Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways.

[1]  D. Graves,et al.  Diabetes enhances mRNA levels of proapoptotic genes and caspase activity, which contribute to impaired healing. , 2006, Diabetes.

[2]  T. Niwa,et al.  Advanced glycation end product modification of bone proteins and bone remodelling: hypothesis and preliminary immunohistochemical findings , 2005, Annals of the rheumatic diseases.

[3]  M. Noda,et al.  Histological evidence of the altered distribution of osteocytes and bone matrix synthesis in klotho-deficient mice. , 2005, Archives of histology and cytology.

[4]  S. Kato,et al.  Advanced Glycation End‐Products Attenuate Human Mesenchymal Stem Cells and Prevent Cognate Differentiation Into Adipose Tissue, Cartilage, and Bone , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  H. Genant,et al.  Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. , 2005, The Journal of clinical investigation.

[6]  D. Graves,et al.  Advanced Glycation End Products Enhance Expression of Pro-apoptotic Genes and Stimulate Fibroblast Apoptosis through Cytoplasmic and Mitochondrial Pathways* , 2005, Journal of Biological Chemistry.

[7]  D. Graves,et al.  FOXO1 Functions as a Master Switch That Regulates Gene Expression Necessary for Tumor Necrosis Factor-induced Fibroblast Apoptosis* , 2005, Journal of Biological Chemistry.

[8]  D. Graves,et al.  TNF‐α in vivo stimulates apoptosis in fibroblasts through caspase‐8 activation and modulates the expression of pro‐apoptotic genes , 2004, Journal of cellular physiology.

[9]  P. Gane,et al.  The triggering of human peritoneal mesothelial cell apoptosis and oncosis by glucose and glycoxydation products. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  S. Yagihashi,et al.  Reduced cell replication and induction of apoptosis by advanced glycation end products in rat Schwann cells. , 2004, Biochemical and biophysical research communications.

[11]  D. Graves,et al.  Diabetes alters the response to bacteria by enhancing fibroblast apoptosis. , 2004, Endocrinology.

[12]  E. Romagnoli,et al.  Skeletal involvement in patients with diabetes mellitus , 2004, Diabetes/metabolism research and reviews.

[13]  R. Weinstein,et al.  Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. , 2004, Endocrinology.

[14]  B. Ortwerth,et al.  2-Ammonio-6-(3-oxidopyridinium-1-yl)hexanoate (OP-lysine) Is a Newly Identified Advanced Glycation End Product in Cataractous and Aged Human Lenses* , 2004, Journal of Biological Chemistry.

[15]  A. Ashkenazi,et al.  Tumor Necrosis Factor An Apoptosis JuNKie? , 2004, Cell.

[16]  A. Schwartz,et al.  Diabetes Mellitus: Does it Affect Bone? , 2003, Calcified Tissue International.

[17]  S. Vatner,et al.  Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart. , 2003, American journal of physiology. Heart and circulatory physiology.

[18]  S. Chae,et al.  JNK/SAPK is required in nitric oxide-induced apoptosis in osteoblasts , 2003, Archives of pharmacal research.

[19]  G. Stein,et al.  Advanced glycation end-products pentosidine and N " -carboxymethyllysine are elevated in serum of patients with osteoporosis , 2003 .

[20]  J. Boehm,et al.  p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases , 2003, Nature Reviews Drug Discovery.

[21]  D. Graves,et al.  A role for advanced glycation end products in diminished bone healing in type 1 diabetes. , 2003, Diabetes.

[22]  M. Kasuga,et al.  Methylglyoxal induces apoptosis through activation of p38 mitogen-activated protein kinase in rat mesangial cells. , 2003, Kidney international.

[23]  D. Saudek,et al.  Advanced glycation endproducts and osteoarthritis , 2003, Current rheumatology reports.

[24]  S. Erkaya,et al.  Evaluation of bone turnover in postmenopausal patients with type 2 diabetes mellitus using biochemical markers and bone mineral density measurements , 2003, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[25]  G. Johnson,et al.  Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases , 2002, Science.

[26]  T. Kataoka,et al.  H-Ras/Mitogen-activated Protein Kinase Pathway Inhibits Integrin-mediated Adhesion and Induces Apoptosis in Osteoblasts* , 2002, The Journal of Biological Chemistry.

[27]  Ego Seeman,et al.  Pathogenesis of bone fragility in women and men , 2002, The Lancet.

[28]  M. Bogoyevitch,et al.  Identification of the Critical Features of a Small Peptide Inhibitor of JNK Activity* , 2002, The Journal of Biological Chemistry.

[29]  H. Vlassara,et al.  Diabetes and advanced glycation endproducts , 2002, Journal of internal medicine.

[30]  K. Ozono,et al.  Role of advanced glycation end products in adynamic bone disease in patients with diabetic nephropathy. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[31]  D. Barrio,et al.  Non-enzymatic glycosylation of a type I collagen matrix: effects on osteoblastic development and oxidative stress , 2001, BMC Cell Biology.

[32]  J. Lemonnier,et al.  Increased osteoblast apoptosis in apert craniosynostosis: role of protein kinase C and interleukin-1. , 2001, The American journal of pathology.

[33]  L. Beilin,et al.  Advanced glycation end-products: a review , 2001, Diabetologia.

[34]  A. Schmidt,et al.  The biology of the receptor for advanced glycation end products and its ligands. , 2000, Biochimica et biophysica acta.

[35]  T. Kislinger,et al.  Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. , 2000, The Journal of clinical investigation.

[36]  J. E. Hale,et al.  Alterations of Cartilage and Collagen Expression during Fracture Healing in Experimental Diabetes , 2000, Connective tissue research.

[37]  T. Kislinger,et al.  N ε-(Carboxymethyl)Lysine Adducts of Proteins Are Ligands for Receptor for Advanced Glycation End Products That Activate Cell Signaling Pathways and Modulate Gene Expression* , 1999, The Journal of Biological Chemistry.

[38]  M. Kohno,et al.  Specific Activation of the p38 Mitogen-activated Protein Kinase Signaling Pathway and Induction of Neurite Outgrowth in PC12 Cells by Bone Morphogenetic Protein-2* , 1999, The Journal of Biological Chemistry.

[39]  C. Y. Wang,et al.  NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. , 1998, Science.

[40]  A. Parfitt,et al.  Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. , 1998, The Journal of clinical investigation.

[41]  T. Kishimoto,et al.  Advanced Glycation Endproducts Stimulate Interleukin‐6 Production by Human Bone‐Derived Cells , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[42]  R. G. Paul,et al.  Glycation of collagen: the basis of its central role in the late complications of ageing and diabetes. , 1996, The international journal of biochemistry & cell biology.

[43]  J. Baynes,et al.  N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. , 1995, Biochemistry.

[44]  E. Wang,et al.  Inhibition of matrix-induced bone differentiation by advanced glycation end-products in rats , 1993, Diabetologia.

[45]  T. Lyons,et al.  Accumulation of Maillard Reaction Products in Skin Collagen in Diabetes and Aging a , 1992, Annals of the New York Academy of Sciences.

[46]  J. Dequeker,et al.  Bone mineral homeostasis in spontaneously diabetic BB rats. II. Impaired bone turnover and decreased osteocalcin synthesis. , 1989, Endocrinology.

[47]  J. Aubin,et al.  Mineralized bone nodules formedin vitro from enzymatically released rat calvaria cell populations , 1986, Calcified Tissue International.

[48]  A. Habeeb,et al.  Determination of free amino groups in proteins by trinitrobenzenesulfonic acid. , 1966, Analytical biochemistry.

[49]  A. Lin,et al.  Role of JNK activation in apoptosis: A double-edged sword , 2005, Cell Research.

[50]  S. Yamagishi,et al.  Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients. , 2005, Medical hypotheses.

[51]  Louis C Gerstenfeld,et al.  Diabetes causes decreased osteoclastogenesis, reduced bone formation, and enhanced apoptosis of osteoblastic cells in bacteria stimulated bone loss. , 2004, Endocrinology.

[52]  G. Stein,et al.  Advanced glycation end-products pentosidine and N epsilon-carboxymethyllysine are elevated in serum of patients with osteoporosis. , 2003, Rheumatology.

[53]  L. Xing,et al.  Apoptosis in Bone Cells , 1998 .

[54]  I. Darby,et al.  Apoptosis is increased in a model of diabetes-impaired wound healing in genetically diabetic mice. , 1997, International Journal of Biochemistry and Cell Biology.

[55]  Rongkun Liu,et al.  Tumor Necrosis Factor- (cid:1) Mediates Diabetes-Enhanced Apoptosis of Matrix-Producing Cells and Impairs Diabetic Healing , 2006 .